Your browser doesn't support javascript.
loading
Real-world treatment intensities and pathways of macular edema following retinal vein occlusion in Korea from Common Data Model in ophthalmology.
Mun, Yongseok; Park, ChulHyoung; Lee, Da Yun; Kim, Tong Min; Jin, Ki Won; Kim, Seok; Chung, Yoo-Ri; Lee, Kihwang; Song, Ji Hun; Roh, Young-Jung; Jee, Donghyun; Kwon, Jin-Woo; Woo, Se Joon; Park, Kyu Hyung; Park, Rae Woong; Yoo, Sooyoung; Chang, Dong-Jin; Park, Sang Jun.
Afiliação
  • Mun Y; Department of Ophthalmology, Hallym University College of Medicine, Kangnam Sacred Heart Hospital, Seoul, South Korea.
  • Park C; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
  • Lee DY; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.
  • Kim TM; Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Jin KW; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.
  • Kim S; Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Chung YR; Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
  • Lee K; Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
  • Song JH; Department of Ophthalmology, Ajou University School of Medicine, Suwon, South Korea.
  • Roh YJ; Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, South Korea.
  • Jee D; Department of Ophthalmology and Visual Science, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Kwon JW; Department of Ophthalmology and Visual Science, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea.
  • Woo SJ; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.
  • Park KH; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea.
  • Park RW; Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, South Korea.
  • Yoo S; Healthcare ICT Research Center, Office of eHealth Research and Businesses, Seoul National University Bundang Hospital, Seongnam, South Korea.
  • Chang DJ; Department of Ophthalmology and Visual Science, Yeouido St. Mary's Hospital, College of Medicine, The Catholic University of Korea, 10, 63-ro, Yeongdeungpo-gu, Seoul, 07345, South Korea. hpalways@songeui.ac.kr.
  • Park SJ; Department of Ophthalmology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, 82, Gumi-ro 173 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 13620, South Korea. sangjunpark@snu.ac.kr.
Sci Rep ; 12(1): 10162, 2022 06 17.
Article em En | MEDLINE | ID: mdl-35715561
ABSTRACT
Despite many studies, optimal treatment sequences or intervals are still questionable in retinal vein occlusion (RVO) macular edema. The aim of this study was to examine the real-world treatment patterns of RVO macular edema. A retrospective analysis of the Observational Medical Outcomes Partnership Common Data Model, a distributed research network, of four large tertiary referral centers (n = 9,202,032) identified 3286 eligible. We visualized treatment pathways (prescription volume and treatment sequence) with sunburst and Sankey diagrams. We calculated the average number of intravitreal injections per patient in the first and second years to evaluate the treatment intensities. Bevacizumab was the most popular first-line drug (80.9%), followed by triamcinolone (15.1%) and dexamethasone (2.28%). Triamcinolone was the most popular drug (8.88%), followed by dexamethasone (6.08%) in patients who began treatment with anti-vascular endothelial growth factor (VEGF) agents. The average number of all intravitreal injections per person decreased in the second year compared with the first year. The average number of injections per person in the first year increased throughout the study. Bevacizumab was the most popular first-line drug and steroids were considered the most common as second-line drugs in patients first treated with anti-VEGF agents. Intensive treatment patterns may cause an increase in intravitreal injections.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oftalmologia / Oclusão da Veia Retiniana / Edema Macular Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oftalmologia / Oclusão da Veia Retiniana / Edema Macular Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Sci Rep Ano de publicação: 2022 Tipo de documento: Article